Zim Laboratories Ltd

Zim Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 May 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the company’s current position as of 01 August 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Zim Laboratories Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. Despite this positive directional change, the stock’s technical indicators present a nuanced picture, with some signals suggesting caution. This analysis delves into the recent price action, key technical indicators including MACD, RSI, moving averages, and their implications for investors navigating the Pharmaceuticals & Biotechnology sector.

Zim Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a strongly bearish outlook to a mildly bullish stance on several key indicators. Despite a recent decline in price, the stock’s technical parameters reveal a complex interplay of bullish and bearish signals, prompting a reassessment of its near-term prospects.

Zim Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish to a bullish trend. Despite a recent day decline of 2.00%, the stock’s technical indicators present a complex picture, with some signals pointing to strength while others suggest caution. This article analyses the latest technical parameters, price momentum, and relative performance against the broader market to provide a comprehensive view for investors.

Zim Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Zim Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

With a decisive surge to Rs 133.95 on 25 Jun 2026, Zim Laboratories Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and sustained outperformance relative to the broader market.

At Rs 127.87, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Zim Laboratories Ltd locked at its upper circuit of 4.99% on 24 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Surging past its previous peak, Zim Laboratories Ltd touched a fresh 52-week high of Rs 129.3 on 23 Jun 2026, marking a significant milestone in its price momentum. This breakout comes after a sustained five-day rally that has propelled the stock up by 18.8%, outperforming its sector by 1.31% on the day.

At Rs 125.4, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Zim Laboratories Ltd locked at its upper circuit of 5% on 22 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Zim Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

At Rs 119.66, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Zim Laboratories Ltd locked at its upper circuit of 5.18% on 19 Jun 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 114.01, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Zim Laboratories Ltd locked at its upper circuit of 4.99% on 18 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Zim Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a strong year-to-date return of 58.0%, the company’s elevated price-to-earnings (P/E) ratio and modest return on capital metrics have prompted a reassessment of its price attractiveness relative to peers and historical benchmarks.

At Rs 113.05, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Zim Laboratories Ltd locked at its upper circuit of 5% on 9 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Zim Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Zim Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.